accountmatching deep cuts in R&D with a $5 billion increase in the group's share buyback program. Arch-rival Merck & Co (MRK.N Some biotech companies, meanwhile, are basking in the success of recent products at a time when Big Pharma has been floundering and...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Analysis: Big Pharma strips down broken R&D engine
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account